Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Gonadotropin (recombinant human follicle-stimulating hormone)

Follitropin alfa

GONAL-f Pen

Dosage form
Tablet
Available strengths
300 IU/0.48 mL, 450 IU/0.72 mL, 900 IU/1.44 mL
Drug class
Gonadotropin (recombinant human follicle-stimulating hormone)
Common brand
GONAL-f Pen

Clinical overview. Follitropin alfa (GONAL-f Pen) is an injectable recombinant follicle-stimulating hormone (r-hFSH) used under close medical supervision to stimulate ovarian follicle development in women undergoing assisted reproductive technology or ovulation induction. Dosing is individualized and requires regular monitoring with ultrasound and estradiol testing. The main safety concern is ovarian hyperstimulation syndrome (OHSS), along with risks of multiple pregnancy and, rarely, blood clots.

Indication

Common therapeutic uses

  • Follitropin alfa is used to stimulate the development of multiple ovarian follicles in ovulatory women undergoing assisted reproductive technologies such as in vitro fertilization, with human chorionic gonadotropin (hCG) given afterward to complete follicular maturation.
  • Follitropin alfa is used to stimulate follicular development in women with hypothalamic-pituitary dysfunction who have absent or infrequent periods (WHO Group II anovulation), followed by hCG to trigger ovulation.
  • It is not authorized for use in men, children, or postmenopausal women, as no data are available to Health Canada for these populations.

Pregnancy

Risk assessment and monitoring considerations

Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.

  • Follitropin alfa is contraindicated during pregnancy, and treatment is discontinued once pregnancy is achieved.
  • High doses in pregnant rats and rabbits increased fetal loss and delivery complications without evidence of a teratogenic (birth defect-causing) effect, though this data has limited relevance since the drug is not used during pregnancy.
  • No adequate, well-controlled studies have been conducted in pregnant women, and no particular pattern of malformation has been identified to date.

Breastfeeding

Infant exposure considerations

  • Follitropin alfa is contraindicated during breastfeeding.
  • It is not known whether follitropin alfa passes into human breast milk, although animal studies show that recombinant FSH is excreted in milk.
  • Prolactin secretion during breastfeeding can also reduce the ovarian response to stimulation.

Geriatrics

Dosing and tolerability considerations

  • Follitropin alfa is not authorized for use in postmenopausal or geriatric women, as no data are available to Health Canada.

Pediatrics

Use in children and adolescents

  • Follitropin alfa is not authorized for use in patients under 18 years of age, as no pediatric data are available to Health Canada.

Dosage & Administration

Practical dosing and administration

  • For assisted reproductive technology in women with unsuppressed gonadotropin levels, treatment is started at 150 IU per day by subcutaneous injection from cycle day 2 or 3; the dose may be adjusted after the first five days, then no more often than every 3 to 5 days, in increments of 37.5 to 150 IU.
  • For assisted reproductive technology in women with pituitary suppression, treatment starts at 225 IU per day by subcutaneous or intramuscular injection, with similar adjustment intervals; doses above 450 IU per day are not generally recommended.
  • For ovulation induction, most often in women with polycystic ovarian syndrome, treatment starts at 75 IU per day; the dose may be increased by up to 37.5 IU after 14 days and again every 7 days if needed, for a maximum of 35 days per cycle unless follicular development is imminent.
  • If ovulation occurs without pregnancy after two treatment cycles at the starting dose, the dose may be increased to 150 IU per day for 7 to 12 days in subsequent cycles.
  • Once adequate follicular development is confirmed by ultrasound or estradiol monitoring, a single dose of hCG is given to trigger final follicular maturation and ovulation.
  • If a dose is missed, the next dose should not be doubled; the patient should contact the physician monitoring treatment.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Little is known about the effects of acute follitropin alfa overdose in humans, aside from the possibility of ovarian hyperstimulation and multiple pregnancies.
  • In animal studies, no acute toxicity was seen even at doses up to 1000 times the human dose, apart from expected effects on the ovaries and uterine lining.

Common side effects

Frequently reported tolerability concerns

  • Injection site reactions, such as pain, redness, bruising, swelling, or irritation, may occur.
  • Headache may occur.
  • Abdominal pain, bloating, or discomfort may occur.
  • Nausea may occur.
  • Vomiting may occur.
  • Diarrhea may occur.
  • Ovarian cysts may develop.
  • Mild to moderate ovarian enlargement may occur.
  • Breast tenderness may occur.
  • Mild to moderate ovarian hyperstimulation syndrome (OHSS) may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Severe ovarian hyperstimulation syndrome (OHSS) can develop, with marked ovarian enlargement and fluid accumulation in the abdomen or chest, and in rare cases can be life-threatening.
  • Ovarian torsion (twisting of an enlarged ovary) may occur as a complication of ovarian enlargement.
  • Blood clots (thromboembolic events), including in the lungs, brain, heart, or limbs, have occurred, rarely resulting in death, particularly in women with existing risk factors.
  • Ectopic pregnancy may occur, particularly in women with pre-existing tubal disease.
  • Multiple pregnancy (twins or more) occurs more often than with natural conception and carries added maternal and fetal risk.
  • Serious lung problems, including collapsed lung tissue, acute respiratory distress, or worsening asthma, have been reported rarely, with rare fatalities.
  • Severe hypersensitivity reactions, including anaphylaxis and shock, have been reported after approval.
  • Ovarian and other reproductive system tumours, both benign and malignant, have been reported in women who underwent multiple courses of fertility treatment, though a causal link has not been confirmed.
  • Seek urgent medical attention for severe abdominal pain or swelling, difficulty breathing, sudden weight gain, or signs of a severe allergic reaction.

Use with caution

Situations requiring closer assessment

  • Use with caution in women with porphyria or a family history of porphyria, since follitropin alfa may trigger an acute attack.
  • Use with caution in women with polycystic ovarian syndrome, who tend to have a more rapid and exaggerated response and a higher OHSS risk.
  • Use with caution in women with personal or family risk factors for blood clots, since gonadotropin therapy may further increase this risk.
  • Use with caution in patients with hepatic impairment, as safety and pharmacokinetics have not been established in this population.
  • Use with caution in patients with renal impairment, as safety and pharmacokinetics have not been established in this population.
  • Use with caution in women in late reproductive age, who have a greater predisposition to endometrial cancer; abnormal uterine bleeding should be fully evaluated before starting treatment.
  • Patients should receive thorough training on self-injection technique with the GONAL-f Pen before starting treatment.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in women with high FSH levels indicating primary ovarian failure.
  • Contraindicated in women with uncontrolled thyroid or adrenal gland dysfunction.
  • Contraindicated in the presence of an intracranial lesion such as a pituitary or hypothalamic tumour.
  • Contraindicated for infertility caused by anything other than anovulation, unless the woman is a candidate for assisted reproductive technology.
  • Contraindicated in women with abnormal uterine bleeding of unknown cause.
  • Contraindicated in women with an ovarian cyst or enlargement of undetermined origin.
  • Contraindicated in women with sex hormone-dependent tumours of the reproductive organs or breast.
  • Contraindicated during pregnancy and breastfeeding.
  • Contraindicated in patients with known hypersensitivity to follitropin alfa, FSH, or any ingredient in the formulation.

Drug interactions

Clinically relevant combinations

  • Clomiphene citrate, luteinizing hormone (LH), and hCG may enhance the follicular response when combined with follitropin alfa, so caution is needed.
  • Use of a GnRH agonist or antagonist to suppress the pituitary gland may change the dose of follitropin alfa required.
  • No other clinically significant drug interactions have been identified.

Food interactions

Meal-related administration

  • No food interactions have been established for this injectable product.

Time of administration

Practical scheduling

  • Injections are typically given once daily at a consistent time during the stimulation phase; the drug can be self-administered using the prefilled pen once training is complete.

Storage

Product handling

  • Store the pen refrigerated at 2°C to 8°C, protected from light, for up to 2 years before first use.
  • Alternatively, the unopened pen may be stored once, for up to 3 months, either refrigerated or at room temperature up to 25°C.
  • After first use, the pen may be kept at room temperature (up to 25°C) for a maximum of 28 days.
  • Do not freeze, and do not use if the solution contains particles or is not clear.

Patient take-away

Key counselling points for a quick closing summary

  • Follitropin alfa (GONAL-f Pen) is an injectable fertility hormone used to stimulate the ovaries under close medical supervision, typically as part of assisted reproductive technology or ovulation induction.
  • Regular monitoring with ultrasound and blood estradiol testing is required throughout treatment to check the ovarian response and reduce the risk of complications.
  • Watch for signs of ovarian hyperstimulation syndrome, such as severe abdominal pain, bloating, nausea, or rapid weight gain, and contact your care team promptly if these occur.
  • Do not double a missed dose; contact your fertility physician for guidance, and store the pen refrigerated, protected from light, and away from children.

References

Source material and product information

  1. Health Canada Product Monograph — Follitropin alfa

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.